...Molecular biology services company Sygnis AG (Xetra:LIO1) raised €10 million ($11.2 million) across two offerings in...
...through the sale of 3.7 million shares at the same price in a private placement. Sygnis...
...officer, will join Sygnis as chief technical officer. Sygnis AG (Xetra:LIO1), Heidelberg, Germany Julian Zhu Innova Biosciences Ltd. Sygnis...

...3 million Price: EUR1.90 Shares after offering: 16.8 million Investors: Existing investors; institutional investors Note: Sygnis...

...every seven held. Under the offering, shareholder Genetrix may acquire up to EUR600,000 ($644,400) in Sygnis...

...India). Oncology company Apogenix GmbH (Heidelberg, Germany) named Peter Willinger CFO. He was CFO of Sygnis Pharma...

...Systasy acquired patents covering Sygnis' Split-TEV Double Switch technology. The IP is part of a broader...
...of two proteins. The technology is based on the tobacco etch virus (TEV) protease, which Sygnis...
...or in a split version (Split-TEV) to detect protein-protein interactions in a "highly sensitive manner." Sygnis...

...billion). No European biotech IPO has come close to the Circassia deal since 2000, when Lion bioscience...
...IPO on Xetra. After selling off its bioinformatics assets, Lion was reincarnated in 2006 as Sygnis Pharma...
...Group plc (LSE:RNVO), Manchester, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stallergenes S.A. (Euronext:GENP), Antony, France Sygnis Pharma...

...€400,741 ($551,219) Shares: 151,223 Price: €2.65 Shares after offering: 10.5 million Investors: Existing investors Note: Sygnis...